ESMO News

Vepdegestrant Prolongs PFS in a Subgroup of Patients with ER-positive, HER2-negative Advanced Breast Cancer with ESR1 mutations

noreply@esmo.org — Mon, 30 Jun 2025 07:06:00 +00:00

Findings from the VERITAC-2 study

FDA Approves Darolutamide for Metastatic Castration-Sensitive Prostate Cancer

noreply@esmo.org — Fri, 27 Jun 2025 07:06:00 +00:00

Evidence for efficacy is based on the results from the ARANOTE study

EMA Recommends Granting a Marketing Authorisation for Inavolisib

noreply@esmo.org — Thu, 26 Jun 2025 07:06:00 +00:00

It is intended for the treatment of adult patients with PIK3CA-mutated, ER-positive, HER2- negative locally advanced and metastatic breast cancer

Improved Survival Benefit with Encorafenib plus Cetuximab plus mFOLFOX6 in First-Line Treatment for Patients with BRAF V600E-mutated mCRC

noreply@esmo.org — Wed, 25 Jun 2025 07:06:00 +00:00

Findings from the BREAKWATER study

ESMO Gastrointestinal Cancers Congress 2025, Barcelona, Spain, 2-5 July

noreply@esmo.org — Wed, 25 Jun 2025 06:06:00 +00:00

The ESMO Gastrointestinal Cancers Congress 2025 will take place between 2-5 July in Barcelona, bringing together leading experts to present new data, share insights, and discuss recent development in the understanding and treatment of gastrointestinal malignancies

Neoadjuvant Nivolumab Plus Chemotherapy Improves OS Among Patients with Resectable NSCLC as Compared with Chemotherapy Alone

noreply@esmo.org — Tue, 24 Jun 2025 07:06:00 +00:00

Findings from the CheckMate 816 study

ESMO Advocates for EU Legislation to Prevent Oncologist Burnout and Ensure Sustainable Care for Patients with Cancer

noreply@esmo.org — Mon, 23 Jun 2025 13:06:00 +00:00

In March 2025, ESMO participated in a consultation on the European Economic and Social Committee (EESC) own-initiative opinion regarding the New Action Plan to implement the European Pillar of Social Rights (EPSR)

Adding Relacorilant To Nab-paclitaxel Prolongs Survival Compared with a Weekly Taxane in Patients with Platinum-Resistant Epithelial Ovarian Cancer

noreply@esmo.org — Mon, 23 Jun 2025 07:06:00 +00:00

Findings from the ROSELLA study

FDA Approves Retifanlimab-dlwr with Carboplatin and Paclitaxel and as a Single Agent for Squamous Cell Carcinoma of the Anal Canal

noreply@esmo.org — Fri, 20 Jun 2025 08:06:00 +00:00

Evidence for efficacy is based on the results from the POD1UM-303/InterAACT 2 and POD1UM-202 studies

EMA Recommends Extension of Therapeutic Indications for Acalabrutinib

noreply@esmo.org — Wed, 18 Jun 2025 08:06:00 +00:00

A new indication concerns the treatment of adult patients with previously untreated CLL in combination with venetoclax

Large DFS Benefit from Adjuvant Cemiplimab Among Patients at High Risk for Recurrence of Cutaneous Squamous Cell Carcinoma

noreply@esmo.org — Wed, 18 Jun 2025 08:06:00 +00:00

Findings from the C-POST study

French Senate Committee Backs ESMO Call to Revise EU Regulation to Support Oncological Research

noreply@esmo.org — Tue, 17 Jun 2025 09:06:00 +00:00

Brussels, 12 June 2025 – The French Senate’s Committee on European Affairs has adopted a political opinion urging the European Commission to revise Regulation (EU) 2017/746 on in vitro diagnostic medical devices (IVDR), aligning with ESMO’s concerns regarding the regulation’s impact on oncological research

Structured Exercise Programme Initiated Soon After the Completion of Adjuvant Chemotherapy for Colon Cancer Improves DFS

noreply@esmo.org — Tue, 17 Jun 2025 07:06:00 +00:00

Findings from the CO.21 CHALLENGE study

Tarlatamab Prolongs OS Over Chemotherapy Among Patients with SCLC Whose Disease Had Progressed During or After Platinum-Based Chemotherapy

noreply@esmo.org — Mon, 16 Jun 2025 07:06:00 +00:00

Findings from the DeLLphi-304 study

ESMO Announces Results of 2025 Elections

noreply@esmo.org — Sat, 14 Jun 2025 07:06:00 +00:00

ESMO has announced the results of its 2025 elections for key leadership positions, following the closure of the voting system on Tuesday, 10 June 2025.

FDA Grants Accelerated Approval to Telisotuzumab Vedotin-tllv for NSCLC with High c-Met Protein Overexpression

noreply@esmo.org — Fri, 13 Jun 2025 07:06:00 +00:00

Evidence for efficacy is based on the results from the LUMINOSITY study

EMA Recommends Extension of Therapeutic Indications for Brentuximab Vedotin

noreply@esmo.org — Thu, 12 Jun 2025 07:06:00 +00:00

A new indication concerns the treatment of adult patients with previously untreated CD30-positive Stage IIB with risk factors, Stage III or Stage IV Hodgkin lymphoma, in combination with BrECADD regimen

ESMO Calls for Oncology-Specific Safeguards in the EU Critical Medicines Act

noreply@esmo.org — Wed, 11 Jun 2025 09:06:00 +00:00

Ensuring equitable access to cancer treatments remains central to EU health security efforts

Elinzanetant Leads To a Significantly Lower Frequency of Vasomotor Symptoms Associated with Endocrine Therapy for HR-positive Breast Cancer

noreply@esmo.org — Wed, 11 Jun 2025 07:06:00 +00:00

Findings from the OASIS-4 study

ESMO Calls for Cancer to Be at the Core of the European Biotechnology Act, Aiming to Deliver Innovation and Tangible Benefits to Patients with Cancer

noreply@esmo.org — Tue, 10 Jun 2025 22:06:00 +00:00

Delivering the right EU policies to support the biotechnology sector holds enormous potential to enhance drug discovery in oncology, enable more targeted and precise cancer therapies, and support personalised medicine.

Vepdegestrant Prolongs PFS in a Subgroup of Patients with ER-positive, HER2-negative Advanced Breast Cancer with ESR1 mutations

noreply@esmo.org — Mon, 30 Jun 2025 07:06:00 +00:00

Findings from the VERITAC-2 study

FDA Approves Darolutamide for Metastatic Castration-Sensitive Prostate Cancer

noreply@esmo.org — Fri, 27 Jun 2025 07:06:00 +00:00

Evidence for efficacy is based on the results from the ARANOTE study

EMA Recommends Granting a Marketing Authorisation for Inavolisib

noreply@esmo.org — Thu, 26 Jun 2025 07:06:00 +00:00

It is intended for the treatment of adult patients with PIK3CA-mutated, ER-positive, HER2- negative locally advanced and metastatic breast cancer

Improved Survival Benefit with Encorafenib plus Cetuximab plus mFOLFOX6 in First-Line Treatment for Patients with BRAF V600E-mutated mCRC

noreply@esmo.org — Wed, 25 Jun 2025 07:06:00 +00:00

Findings from the BREAKWATER study

ESMO Gastrointestinal Cancers Congress 2025, Barcelona, Spain, 2-5 July

noreply@esmo.org — Wed, 25 Jun 2025 06:06:00 +00:00

Neoadjuvant Nivolumab Plus Chemotherapy Improves OS Among Patients with Resectable NSCLC as Compared with Chemotherapy Alone

noreply@esmo.org — Tue, 24 Jun 2025 07:06:00 +00:00

Findings from the CheckMate 816 study

ESMO Advocates for EU Legislation to Prevent Oncologist Burnout and Ensure Sustainable Care for Patients with Cancer

noreply@esmo.org — Mon, 23 Jun 2025 13:06:00 +00:00

Adding Relacorilant To Nab-paclitaxel Prolongs Survival Compared with a Weekly Taxane in Patients with Platinum-Resistant Epithelial Ovarian Cancer

noreply@esmo.org — Mon, 23 Jun 2025 07:06:00 +00:00

Findings from the ROSELLA study

FDA Approves Retifanlimab-dlwr with Carboplatin and Paclitaxel and as a Single Agent for Squamous Cell Carcinoma of the Anal Canal

noreply@esmo.org — Fri, 20 Jun 2025 08:06:00 +00:00

Evidence for efficacy is based on the results from the POD1UM-303/InterAACT 2 and POD1UM-202 studies

EMA Recommends Extension of Therapeutic Indications for Acalabrutinib

noreply@esmo.org — Wed, 18 Jun 2025 08:06:00 +00:00

A new indication concerns the treatment of adult patients with previously untreated CLL in combination with venetoclax

Large DFS Benefit from Adjuvant Cemiplimab Among Patients at High Risk for Recurrence of Cutaneous Squamous Cell Carcinoma

noreply@esmo.org — Wed, 18 Jun 2025 08:06:00 +00:00

Findings from the C-POST study

French Senate Committee Backs ESMO Call to Revise EU Regulation to Support Oncological Research

noreply@esmo.org — Tue, 17 Jun 2025 09:06:00 +00:00

Structured Exercise Programme Initiated Soon After the Completion of Adjuvant Chemotherapy for Colon Cancer Improves DFS

noreply@esmo.org — Tue, 17 Jun 2025 07:06:00 +00:00

Findings from the CO.21 CHALLENGE study

Tarlatamab Prolongs OS Over Chemotherapy Among Patients with SCLC Whose Disease Had Progressed During or After Platinum-Based Chemotherapy

noreply@esmo.org — Mon, 16 Jun 2025 07:06:00 +00:00

Findings from the DeLLphi-304 study

ESMO Announces Results of 2025 Elections

noreply@esmo.org — Sat, 14 Jun 2025 07:06:00 +00:00

ESMO has announced the results of its 2025 elections for key leadership positions, following the closure of the voting system on Tuesday, 10 June 2025.

FDA Grants Accelerated Approval to Telisotuzumab Vedotin-tllv for NSCLC with High c-Met Protein Overexpression

noreply@esmo.org — Fri, 13 Jun 2025 07:06:00 +00:00

Evidence for efficacy is based on the results from the LUMINOSITY study

EMA Recommends Extension of Therapeutic Indications for Brentuximab Vedotin

noreply@esmo.org — Thu, 12 Jun 2025 07:06:00 +00:00

ESMO Calls for Oncology-Specific Safeguards in the EU Critical Medicines Act

noreply@esmo.org — Wed, 11 Jun 2025 09:06:00 +00:00

Ensuring equitable access to cancer treatments remains central to EU health security efforts

Elinzanetant Leads To a Significantly Lower Frequency of Vasomotor Symptoms Associated with Endocrine Therapy for HR-positive Breast Cancer

noreply@esmo.org — Wed, 11 Jun 2025 07:06:00 +00:00

Findings from the OASIS-4 study

ESMO Calls for Cancer to Be at the Core of the European Biotechnology Act, Aiming to Deliver Innovation and Tangible Benefits to Patients with Cancer

noreply@esmo.org — Tue, 10 Jun 2025 22:06:00 +00:00

Vepdegestrant Prolongs PFS in a Subgroup of Patients with ER-positive, HER2-negative Advanced Breast Cancer with ESR1 mutations

noreply@esmo.org — Mon, 30 Jun 2025 07:06:00 +00:00

Findings from the VERITAC-2 study

FDA Approves Darolutamide for Metastatic Castration-Sensitive Prostate Cancer

noreply@esmo.org — Fri, 27 Jun 2025 07:06:00 +00:00

Evidence for efficacy is based on the results from the ARANOTE study

EMA Recommends Granting a Marketing Authorisation for Inavolisib

noreply@esmo.org — Thu, 26 Jun 2025 07:06:00 +00:00

It is intended for the treatment of adult patients with PIK3CA-mutated, ER-positive, HER2- negative locally advanced and metastatic breast cancer

Improved Survival Benefit with Encorafenib plus Cetuximab plus mFOLFOX6 in First-Line Treatment for Patients with BRAF V600E-mutated mCRC

noreply@esmo.org — Wed, 25 Jun 2025 07:06:00 +00:00

Findings from the BREAKWATER study

ESMO Gastrointestinal Cancers Congress 2025, Barcelona, Spain, 2-5 July

noreply@esmo.org — Wed, 25 Jun 2025 06:06:00 +00:00

Neoadjuvant Nivolumab Plus Chemotherapy Improves OS Among Patients with Resectable NSCLC as Compared with Chemotherapy Alone

noreply@esmo.org — Tue, 24 Jun 2025 07:06:00 +00:00

Findings from the CheckMate 816 study

ESMO Advocates for EU Legislation to Prevent Oncologist Burnout and Ensure Sustainable Care for Patients with Cancer

noreply@esmo.org — Mon, 23 Jun 2025 13:06:00 +00:00

Adding Relacorilant To Nab-paclitaxel Prolongs Survival Compared with a Weekly Taxane in Patients with Platinum-Resistant Epithelial Ovarian Cancer

noreply@esmo.org — Mon, 23 Jun 2025 07:06:00 +00:00

Findings from the ROSELLA study

FDA Approves Retifanlimab-dlwr with Carboplatin and Paclitaxel and as a Single Agent for Squamous Cell Carcinoma of the Anal Canal

noreply@esmo.org — Fri, 20 Jun 2025 08:06:00 +00:00

Evidence for efficacy is based on the results from the POD1UM-303/InterAACT 2 and POD1UM-202 studies

EMA Recommends Extension of Therapeutic Indications for Acalabrutinib

noreply@esmo.org — Wed, 18 Jun 2025 08:06:00 +00:00

A new indication concerns the treatment of adult patients with previously untreated CLL in combination with venetoclax

Large DFS Benefit from Adjuvant Cemiplimab Among Patients at High Risk for Recurrence of Cutaneous Squamous Cell Carcinoma

noreply@esmo.org — Wed, 18 Jun 2025 08:06:00 +00:00

Findings from the C-POST study

French Senate Committee Backs ESMO Call to Revise EU Regulation to Support Oncological Research

noreply@esmo.org — Tue, 17 Jun 2025 09:06:00 +00:00

Structured Exercise Programme Initiated Soon After the Completion of Adjuvant Chemotherapy for Colon Cancer Improves DFS

noreply@esmo.org — Tue, 17 Jun 2025 07:06:00 +00:00

Findings from the CO.21 CHALLENGE study

Tarlatamab Prolongs OS Over Chemotherapy Among Patients with SCLC Whose Disease Had Progressed During or After Platinum-Based Chemotherapy

noreply@esmo.org — Mon, 16 Jun 2025 07:06:00 +00:00

Findings from the DeLLphi-304 study

ESMO Announces Results of 2025 Elections

noreply@esmo.org — Sat, 14 Jun 2025 07:06:00 +00:00

ESMO has announced the results of its 2025 elections for key leadership positions, following the closure of the voting system on Tuesday, 10 June 2025.

FDA Grants Accelerated Approval to Telisotuzumab Vedotin-tllv for NSCLC with High c-Met Protein Overexpression

noreply@esmo.org — Fri, 13 Jun 2025 07:06:00 +00:00

Evidence for efficacy is based on the results from the LUMINOSITY study

EMA Recommends Extension of Therapeutic Indications for Brentuximab Vedotin

noreply@esmo.org — Thu, 12 Jun 2025 07:06:00 +00:00

ESMO Calls for Oncology-Specific Safeguards in the EU Critical Medicines Act

noreply@esmo.org — Wed, 11 Jun 2025 09:06:00 +00:00

Ensuring equitable access to cancer treatments remains central to EU health security efforts

Elinzanetant Leads To a Significantly Lower Frequency of Vasomotor Symptoms Associated with Endocrine Therapy for HR-positive Breast Cancer

noreply@esmo.org — Wed, 11 Jun 2025 07:06:00 +00:00

Findings from the OASIS-4 study

ESMO Calls for Cancer to Be at the Core of the European Biotechnology Act, Aiming to Deliver Innovation and Tangible Benefits to Patients with Cancer

noreply@esmo.org — Tue, 10 Jun 2025 22:06:00 +00:00

Vepdegestrant Prolongs PFS in a Subgroup of Patients with ER-positive, HER2-negative Advanced Breast Cancer with ESR1 mutations

noreply@esmo.org — Mon, 30 Jun 2025 07:06:00 +00:00

Findings from the VERITAC-2 study

FDA Approves Darolutamide for Metastatic Castration-Sensitive Prostate Cancer

noreply@esmo.org — Fri, 27 Jun 2025 07:06:00 +00:00

Evidence for efficacy is based on the results from the ARANOTE study

EMA Recommends Granting a Marketing Authorisation for Inavolisib

noreply@esmo.org — Thu, 26 Jun 2025 07:06:00 +00:00

It is intended for the treatment of adult patients with PIK3CA-mutated, ER-positive, HER2- negative locally advanced and metastatic breast cancer

Improved Survival Benefit with Encorafenib plus Cetuximab plus mFOLFOX6 in First-Line Treatment for Patients with BRAF V600E-mutated mCRC

noreply@esmo.org — Wed, 25 Jun 2025 07:06:00 +00:00

Findings from the BREAKWATER study

ESMO Gastrointestinal Cancers Congress 2025, Barcelona, Spain, 2-5 July

noreply@esmo.org — Wed, 25 Jun 2025 06:06:00 +00:00

Neoadjuvant Nivolumab Plus Chemotherapy Improves OS Among Patients with Resectable NSCLC as Compared with Chemotherapy Alone

noreply@esmo.org — Tue, 24 Jun 2025 07:06:00 +00:00

Findings from the CheckMate 816 study

ESMO Advocates for EU Legislation to Prevent Oncologist Burnout and Ensure Sustainable Care for Patients with Cancer

noreply@esmo.org — Mon, 23 Jun 2025 13:06:00 +00:00

Adding Relacorilant To Nab-paclitaxel Prolongs Survival Compared with a Weekly Taxane in Patients with Platinum-Resistant Epithelial Ovarian Cancer

noreply@esmo.org — Mon, 23 Jun 2025 07:06:00 +00:00

Findings from the ROSELLA study

FDA Approves Retifanlimab-dlwr with Carboplatin and Paclitaxel and as a Single Agent for Squamous Cell Carcinoma of the Anal Canal

noreply@esmo.org — Fri, 20 Jun 2025 08:06:00 +00:00

Evidence for efficacy is based on the results from the POD1UM-303/InterAACT 2 and POD1UM-202 studies

EMA Recommends Extension of Therapeutic Indications for Acalabrutinib

noreply@esmo.org — Wed, 18 Jun 2025 08:06:00 +00:00

A new indication concerns the treatment of adult patients with previously untreated CLL in combination with venetoclax

Large DFS Benefit from Adjuvant Cemiplimab Among Patients at High Risk for Recurrence of Cutaneous Squamous Cell Carcinoma

noreply@esmo.org — Wed, 18 Jun 2025 08:06:00 +00:00

Findings from the C-POST study

French Senate Committee Backs ESMO Call to Revise EU Regulation to Support Oncological Research

noreply@esmo.org — Tue, 17 Jun 2025 09:06:00 +00:00

Structured Exercise Programme Initiated Soon After the Completion of Adjuvant Chemotherapy for Colon Cancer Improves DFS

noreply@esmo.org — Tue, 17 Jun 2025 07:06:00 +00:00

Findings from the CO.21 CHALLENGE study

Tarlatamab Prolongs OS Over Chemotherapy Among Patients with SCLC Whose Disease Had Progressed During or After Platinum-Based Chemotherapy

noreply@esmo.org — Mon, 16 Jun 2025 07:06:00 +00:00

Findings from the DeLLphi-304 study

ESMO Announces Results of 2025 Elections

noreply@esmo.org — Sat, 14 Jun 2025 07:06:00 +00:00

ESMO has announced the results of its 2025 elections for key leadership positions, following the closure of the voting system on Tuesday, 10 June 2025.

FDA Grants Accelerated Approval to Telisotuzumab Vedotin-tllv for NSCLC with High c-Met Protein Overexpression

noreply@esmo.org — Fri, 13 Jun 2025 07:06:00 +00:00

Evidence for efficacy is based on the results from the LUMINOSITY study

EMA Recommends Extension of Therapeutic Indications for Brentuximab Vedotin

noreply@esmo.org — Thu, 12 Jun 2025 07:06:00 +00:00

ESMO Calls for Oncology-Specific Safeguards in the EU Critical Medicines Act

noreply@esmo.org — Wed, 11 Jun 2025 09:06:00 +00:00

Ensuring equitable access to cancer treatments remains central to EU health security efforts

Elinzanetant Leads To a Significantly Lower Frequency of Vasomotor Symptoms Associated with Endocrine Therapy for HR-positive Breast Cancer

noreply@esmo.org — Wed, 11 Jun 2025 07:06:00 +00:00

Findings from the OASIS-4 study

ESMO Calls for Cancer to Be at the Core of the European Biotechnology Act, Aiming to Deliver Innovation and Tangible Benefits to Patients with Cancer

noreply@esmo.org — Tue, 10 Jun 2025 22:06:00 +00:00

Vepdegestrant Prolongs PFS in a Subgroup of Patients with ER-positive, HER2-negative Advanced Breast Cancer with ESR1 mutations

noreply@esmo.org — Mon, 30 Jun 2025 07:06:00 +00:00

Findings from the VERITAC-2 study

FDA Approves Darolutamide for Metastatic Castration-Sensitive Prostate Cancer

noreply@esmo.org — Fri, 27 Jun 2025 07:06:00 +00:00

Evidence for efficacy is based on the results from the ARANOTE study

EMA Recommends Granting a Marketing Authorisation for Inavolisib

noreply@esmo.org — Thu, 26 Jun 2025 07:06:00 +00:00

It is intended for the treatment of adult patients with PIK3CA-mutated, ER-positive, HER2- negative locally advanced and metastatic breast cancer

Improved Survival Benefit with Encorafenib plus Cetuximab plus mFOLFOX6 in First-Line Treatment for Patients with BRAF V600E-mutated mCRC

noreply@esmo.org — Wed, 25 Jun 2025 07:06:00 +00:00

Findings from the BREAKWATER study

ESMO Gastrointestinal Cancers Congress 2025, Barcelona, Spain, 2-5 July

noreply@esmo.org — Wed, 25 Jun 2025 06:06:00 +00:00

Neoadjuvant Nivolumab Plus Chemotherapy Improves OS Among Patients with Resectable NSCLC as Compared with Chemotherapy Alone

noreply@esmo.org — Tue, 24 Jun 2025 07:06:00 +00:00

Findings from the CheckMate 816 study

ESMO Advocates for EU Legislation to Prevent Oncologist Burnout and Ensure Sustainable Care for Patients with Cancer

noreply@esmo.org — Mon, 23 Jun 2025 13:06:00 +00:00

Adding Relacorilant To Nab-paclitaxel Prolongs Survival Compared with a Weekly Taxane in Patients with Platinum-Resistant Epithelial Ovarian Cancer

noreply@esmo.org — Mon, 23 Jun 2025 07:06:00 +00:00

Findings from the ROSELLA study

FDA Approves Retifanlimab-dlwr with Carboplatin and Paclitaxel and as a Single Agent for Squamous Cell Carcinoma of the Anal Canal

noreply@esmo.org — Fri, 20 Jun 2025 08:06:00 +00:00

Evidence for efficacy is based on the results from the POD1UM-303/InterAACT 2 and POD1UM-202 studies

EMA Recommends Extension of Therapeutic Indications for Acalabrutinib

noreply@esmo.org — Wed, 18 Jun 2025 08:06:00 +00:00

A new indication concerns the treatment of adult patients with previously untreated CLL in combination with venetoclax

Large DFS Benefit from Adjuvant Cemiplimab Among Patients at High Risk for Recurrence of Cutaneous Squamous Cell Carcinoma

noreply@esmo.org — Wed, 18 Jun 2025 08:06:00 +00:00

Findings from the C-POST study

French Senate Committee Backs ESMO Call to Revise EU Regulation to Support Oncological Research

noreply@esmo.org — Tue, 17 Jun 2025 09:06:00 +00:00

Structured Exercise Programme Initiated Soon After the Completion of Adjuvant Chemotherapy for Colon Cancer Improves DFS

noreply@esmo.org — Tue, 17 Jun 2025 07:06:00 +00:00

Findings from the CO.21 CHALLENGE study

Tarlatamab Prolongs OS Over Chemotherapy Among Patients with SCLC Whose Disease Had Progressed During or After Platinum-Based Chemotherapy

noreply@esmo.org — Mon, 16 Jun 2025 07:06:00 +00:00

Findings from the DeLLphi-304 study

ESMO Announces Results of 2025 Elections

noreply@esmo.org — Sat, 14 Jun 2025 07:06:00 +00:00

ESMO has announced the results of its 2025 elections for key leadership positions, following the closure of the voting system on Tuesday, 10 June 2025.

FDA Grants Accelerated Approval to Telisotuzumab Vedotin-tllv for NSCLC with High c-Met Protein Overexpression

noreply@esmo.org — Fri, 13 Jun 2025 07:06:00 +00:00

Evidence for efficacy is based on the results from the LUMINOSITY study

EMA Recommends Extension of Therapeutic Indications for Brentuximab Vedotin

noreply@esmo.org — Thu, 12 Jun 2025 07:06:00 +00:00

ESMO Calls for Oncology-Specific Safeguards in the EU Critical Medicines Act

noreply@esmo.org — Wed, 11 Jun 2025 09:06:00 +00:00

Ensuring equitable access to cancer treatments remains central to EU health security efforts

Elinzanetant Leads To a Significantly Lower Frequency of Vasomotor Symptoms Associated with Endocrine Therapy for HR-positive Breast Cancer

noreply@esmo.org — Wed, 11 Jun 2025 07:06:00 +00:00

Findings from the OASIS-4 study

ESMO Calls for Cancer to Be at the Core of the European Biotechnology Act, Aiming to Deliver Innovation and Tangible Benefits to Patients with Cancer

noreply@esmo.org — Tue, 10 Jun 2025 22:06:00 +00:00

Vepdegestrant Prolongs PFS in a Subgroup of Patients with ER-positive, HER2-negative Advanced Breast Cancer with ESR1 mutations

noreply@esmo.org — Mon, 30 Jun 2025 07:06:00 +00:00

Findings from the VERITAC-2 study

FDA Approves Darolutamide for Metastatic Castration-Sensitive Prostate Cancer

noreply@esmo.org — Fri, 27 Jun 2025 07:06:00 +00:00

Evidence for efficacy is based on the results from the ARANOTE study

EMA Recommends Granting a Marketing Authorisation for Inavolisib

noreply@esmo.org — Thu, 26 Jun 2025 07:06:00 +00:00

It is intended for the treatment of adult patients with PIK3CA-mutated, ER-positive, HER2- negative locally advanced and metastatic breast cancer

Improved Survival Benefit with Encorafenib plus Cetuximab plus mFOLFOX6 in First-Line Treatment for Patients with BRAF V600E-mutated mCRC

noreply@esmo.org — Wed, 25 Jun 2025 07:06:00 +00:00

Findings from the BREAKWATER study

ESMO Gastrointestinal Cancers Congress 2025, Barcelona, Spain, 2-5 July

noreply@esmo.org — Wed, 25 Jun 2025 06:06:00 +00:00

Neoadjuvant Nivolumab Plus Chemotherapy Improves OS Among Patients with Resectable NSCLC as Compared with Chemotherapy Alone

noreply@esmo.org — Tue, 24 Jun 2025 07:06:00 +00:00

Findings from the CheckMate 816 study

ESMO Advocates for EU Legislation to Prevent Oncologist Burnout and Ensure Sustainable Care for Patients with Cancer

noreply@esmo.org — Mon, 23 Jun 2025 13:06:00 +00:00

Adding Relacorilant To Nab-paclitaxel Prolongs Survival Compared with a Weekly Taxane in Patients with Platinum-Resistant Epithelial Ovarian Cancer

noreply@esmo.org — Mon, 23 Jun 2025 07:06:00 +00:00

Findings from the ROSELLA study

FDA Approves Retifanlimab-dlwr with Carboplatin and Paclitaxel and as a Single Agent for Squamous Cell Carcinoma of the Anal Canal

noreply@esmo.org — Fri, 20 Jun 2025 08:06:00 +00:00

Evidence for efficacy is based on the results from the POD1UM-303/InterAACT 2 and POD1UM-202 studies

EMA Recommends Extension of Therapeutic Indications for Acalabrutinib

noreply@esmo.org — Wed, 18 Jun 2025 08:06:00 +00:00

A new indication concerns the treatment of adult patients with previously untreated CLL in combination with venetoclax

Large DFS Benefit from Adjuvant Cemiplimab Among Patients at High Risk for Recurrence of Cutaneous Squamous Cell Carcinoma

noreply@esmo.org — Wed, 18 Jun 2025 08:06:00 +00:00

Findings from the C-POST study

French Senate Committee Backs ESMO Call to Revise EU Regulation to Support Oncological Research

noreply@esmo.org — Tue, 17 Jun 2025 09:06:00 +00:00

Structured Exercise Programme Initiated Soon After the Completion of Adjuvant Chemotherapy for Colon Cancer Improves DFS

noreply@esmo.org — Tue, 17 Jun 2025 07:06:00 +00:00

Findings from the CO.21 CHALLENGE study

Tarlatamab Prolongs OS Over Chemotherapy Among Patients with SCLC Whose Disease Had Progressed During or After Platinum-Based Chemotherapy

noreply@esmo.org — Mon, 16 Jun 2025 07:06:00 +00:00

Findings from the DeLLphi-304 study

ESMO Announces Results of 2025 Elections

noreply@esmo.org — Sat, 14 Jun 2025 07:06:00 +00:00

ESMO has announced the results of its 2025 elections for key leadership positions, following the closure of the voting system on Tuesday, 10 June 2025.

FDA Grants Accelerated Approval to Telisotuzumab Vedotin-tllv for NSCLC with High c-Met Protein Overexpression

noreply@esmo.org — Fri, 13 Jun 2025 07:06:00 +00:00

Evidence for efficacy is based on the results from the LUMINOSITY study

EMA Recommends Extension of Therapeutic Indications for Brentuximab Vedotin

noreply@esmo.org — Thu, 12 Jun 2025 07:06:00 +00:00

ESMO Calls for Oncology-Specific Safeguards in the EU Critical Medicines Act

noreply@esmo.org — Wed, 11 Jun 2025 09:06:00 +00:00

Ensuring equitable access to cancer treatments remains central to EU health security efforts

Elinzanetant Leads To a Significantly Lower Frequency of Vasomotor Symptoms Associated with Endocrine Therapy for HR-positive Breast Cancer

noreply@esmo.org — Wed, 11 Jun 2025 07:06:00 +00:00

Findings from the OASIS-4 study

ESMO Calls for Cancer to Be at the Core of the European Biotechnology Act, Aiming to Deliver Innovation and Tangible Benefits to Patients with Cancer

noreply@esmo.org — Tue, 10 Jun 2025 22:06:00 +00:00

Vepdegestrant Prolongs PFS in a Subgroup of Patients with ER-positive, HER2-negative Advanced Breast Cancer with ESR1 mutations

noreply@esmo.org — Mon, 30 Jun 2025 07:06:00 +00:00

Findings from the VERITAC-2 study

FDA Approves Darolutamide for Metastatic Castration-Sensitive Prostate Cancer

noreply@esmo.org — Fri, 27 Jun 2025 07:06:00 +00:00

Evidence for efficacy is based on the results from the ARANOTE study

EMA Recommends Granting a Marketing Authorisation for Inavolisib

noreply@esmo.org — Thu, 26 Jun 2025 07:06:00 +00:00

It is intended for the treatment of adult patients with PIK3CA-mutated, ER-positive, HER2- negative locally advanced and metastatic breast cancer

Improved Survival Benefit with Encorafenib plus Cetuximab plus mFOLFOX6 in First-Line Treatment for Patients with BRAF V600E-mutated mCRC

noreply@esmo.org — Wed, 25 Jun 2025 07:06:00 +00:00

Findings from the BREAKWATER study

ESMO Gastrointestinal Cancers Congress 2025, Barcelona, Spain, 2-5 July

noreply@esmo.org — Wed, 25 Jun 2025 06:06:00 +00:00

Neoadjuvant Nivolumab Plus Chemotherapy Improves OS Among Patients with Resectable NSCLC as Compared with Chemotherapy Alone

noreply@esmo.org — Tue, 24 Jun 2025 07:06:00 +00:00

Findings from the CheckMate 816 study

ESMO Advocates for EU Legislation to Prevent Oncologist Burnout and Ensure Sustainable Care for Patients with Cancer

noreply@esmo.org — Mon, 23 Jun 2025 13:06:00 +00:00

Adding Relacorilant To Nab-paclitaxel Prolongs Survival Compared with a Weekly Taxane in Patients with Platinum-Resistant Epithelial Ovarian Cancer

noreply@esmo.org — Mon, 23 Jun 2025 07:06:00 +00:00

Findings from the ROSELLA study

FDA Approves Retifanlimab-dlwr with Carboplatin and Paclitaxel and as a Single Agent for Squamous Cell Carcinoma of the Anal Canal

noreply@esmo.org — Fri, 20 Jun 2025 08:06:00 +00:00

Evidence for efficacy is based on the results from the POD1UM-303/InterAACT 2 and POD1UM-202 studies

EMA Recommends Extension of Therapeutic Indications for Acalabrutinib

noreply@esmo.org — Wed, 18 Jun 2025 08:06:00 +00:00

A new indication concerns the treatment of adult patients with previously untreated CLL in combination with venetoclax

Large DFS Benefit from Adjuvant Cemiplimab Among Patients at High Risk for Recurrence of Cutaneous Squamous Cell Carcinoma

noreply@esmo.org — Wed, 18 Jun 2025 08:06:00 +00:00

Findings from the C-POST study

French Senate Committee Backs ESMO Call to Revise EU Regulation to Support Oncological Research

noreply@esmo.org — Tue, 17 Jun 2025 09:06:00 +00:00

Structured Exercise Programme Initiated Soon After the Completion of Adjuvant Chemotherapy for Colon Cancer Improves DFS

noreply@esmo.org — Tue, 17 Jun 2025 07:06:00 +00:00

Findings from the CO.21 CHALLENGE study

Tarlatamab Prolongs OS Over Chemotherapy Among Patients with SCLC Whose Disease Had Progressed During or After Platinum-Based Chemotherapy

noreply@esmo.org — Mon, 16 Jun 2025 07:06:00 +00:00

Findings from the DeLLphi-304 study

ESMO Announces Results of 2025 Elections

noreply@esmo.org — Sat, 14 Jun 2025 07:06:00 +00:00

ESMO has announced the results of its 2025 elections for key leadership positions, following the closure of the voting system on Tuesday, 10 June 2025.

FDA Grants Accelerated Approval to Telisotuzumab Vedotin-tllv for NSCLC with High c-Met Protein Overexpression

noreply@esmo.org — Fri, 13 Jun 2025 07:06:00 +00:00

Evidence for efficacy is based on the results from the LUMINOSITY study

EMA Recommends Extension of Therapeutic Indications for Brentuximab Vedotin

noreply@esmo.org — Thu, 12 Jun 2025 07:06:00 +00:00

ESMO Calls for Oncology-Specific Safeguards in the EU Critical Medicines Act

noreply@esmo.org — Wed, 11 Jun 2025 09:06:00 +00:00

Ensuring equitable access to cancer treatments remains central to EU health security efforts

Elinzanetant Leads To a Significantly Lower Frequency of Vasomotor Symptoms Associated with Endocrine Therapy for HR-positive Breast Cancer

noreply@esmo.org — Wed, 11 Jun 2025 07:06:00 +00:00

Findings from the OASIS-4 study

ESMO Calls for Cancer to Be at the Core of the European Biotechnology Act, Aiming to Deliver Innovation and Tangible Benefits to Patients with Cancer

noreply@esmo.org — Tue, 10 Jun 2025 22:06:00 +00:00

Vepdegestrant Prolongs PFS in a Subgroup of Patients with ER-positive, HER2-negative Advanced Breast Cancer with ESR1 mutations

noreply@esmo.org — Mon, 30 Jun 2025 07:06:00 +00:00

Findings from the VERITAC-2 study

FDA Approves Darolutamide for Metastatic Castration-Sensitive Prostate Cancer

noreply@esmo.org — Fri, 27 Jun 2025 07:06:00 +00:00

Evidence for efficacy is based on the results from the ARANOTE study

EMA Recommends Granting a Marketing Authorisation for Inavolisib

noreply@esmo.org — Thu, 26 Jun 2025 07:06:00 +00:00

It is intended for the treatment of adult patients with PIK3CA-mutated, ER-positive, HER2- negative locally advanced and metastatic breast cancer

Improved Survival Benefit with Encorafenib plus Cetuximab plus mFOLFOX6 in First-Line Treatment for Patients with BRAF V600E-mutated mCRC

noreply@esmo.org — Wed, 25 Jun 2025 07:06:00 +00:00

Findings from the BREAKWATER study

ESMO Gastrointestinal Cancers Congress 2025, Barcelona, Spain, 2-5 July

noreply@esmo.org — Wed, 25 Jun 2025 06:06:00 +00:00

Neoadjuvant Nivolumab Plus Chemotherapy Improves OS Among Patients with Resectable NSCLC as Compared with Chemotherapy Alone

noreply@esmo.org — Tue, 24 Jun 2025 07:06:00 +00:00

Findings from the CheckMate 816 study

ESMO Advocates for EU Legislation to Prevent Oncologist Burnout and Ensure Sustainable Care for Patients with Cancer

noreply@esmo.org — Mon, 23 Jun 2025 13:06:00 +00:00

Adding Relacorilant To Nab-paclitaxel Prolongs Survival Compared with a Weekly Taxane in Patients with Platinum-Resistant Epithelial Ovarian Cancer

noreply@esmo.org — Mon, 23 Jun 2025 07:06:00 +00:00

Findings from the ROSELLA study

FDA Approves Retifanlimab-dlwr with Carboplatin and Paclitaxel and as a Single Agent for Squamous Cell Carcinoma of the Anal Canal

noreply@esmo.org — Fri, 20 Jun 2025 08:06:00 +00:00

Evidence for efficacy is based on the results from the POD1UM-303/InterAACT 2 and POD1UM-202 studies

EMA Recommends Extension of Therapeutic Indications for Acalabrutinib

noreply@esmo.org — Wed, 18 Jun 2025 08:06:00 +00:00

A new indication concerns the treatment of adult patients with previously untreated CLL in combination with venetoclax

Large DFS Benefit from Adjuvant Cemiplimab Among Patients at High Risk for Recurrence of Cutaneous Squamous Cell Carcinoma

noreply@esmo.org — Wed, 18 Jun 2025 08:06:00 +00:00

Findings from the C-POST study

French Senate Committee Backs ESMO Call to Revise EU Regulation to Support Oncological Research

noreply@esmo.org — Tue, 17 Jun 2025 09:06:00 +00:00

Structured Exercise Programme Initiated Soon After the Completion of Adjuvant Chemotherapy for Colon Cancer Improves DFS

noreply@esmo.org — Tue, 17 Jun 2025 07:06:00 +00:00

Findings from the CO.21 CHALLENGE study

Tarlatamab Prolongs OS Over Chemotherapy Among Patients with SCLC Whose Disease Had Progressed During or After Platinum-Based Chemotherapy

noreply@esmo.org — Mon, 16 Jun 2025 07:06:00 +00:00

Findings from the DeLLphi-304 study

ESMO Announces Results of 2025 Elections

noreply@esmo.org — Sat, 14 Jun 2025 07:06:00 +00:00

ESMO has announced the results of its 2025 elections for key leadership positions, following the closure of the voting system on Tuesday, 10 June 2025.

FDA Grants Accelerated Approval to Telisotuzumab Vedotin-tllv for NSCLC with High c-Met Protein Overexpression

noreply@esmo.org — Fri, 13 Jun 2025 07:06:00 +00:00

Evidence for efficacy is based on the results from the LUMINOSITY study

EMA Recommends Extension of Therapeutic Indications for Brentuximab Vedotin

noreply@esmo.org — Thu, 12 Jun 2025 07:06:00 +00:00

ESMO Calls for Oncology-Specific Safeguards in the EU Critical Medicines Act

noreply@esmo.org — Wed, 11 Jun 2025 09:06:00 +00:00

Ensuring equitable access to cancer treatments remains central to EU health security efforts

Elinzanetant Leads To a Significantly Lower Frequency of Vasomotor Symptoms Associated with Endocrine Therapy for HR-positive Breast Cancer

noreply@esmo.org — Wed, 11 Jun 2025 07:06:00 +00:00

Findings from the OASIS-4 study

ESMO Calls for Cancer to Be at the Core of the European Biotechnology Act, Aiming to Deliver Innovation and Tangible Benefits to Patients with Cancer

noreply@esmo.org — Tue, 10 Jun 2025 22:06:00 +00:00

Vepdegestrant Prolongs PFS in a Subgroup of Patients with ER-positive, HER2-negative Advanced Breast Cancer with ESR1 mutations

noreply@esmo.org — Mon, 30 Jun 2025 07:06:00 +00:00

Findings from the VERITAC-2 study

FDA Approves Darolutamide for Metastatic Castration-Sensitive Prostate Cancer

noreply@esmo.org — Fri, 27 Jun 2025 07:06:00 +00:00

Evidence for efficacy is based on the results from the ARANOTE study

EMA Recommends Granting a Marketing Authorisation for Inavolisib

noreply@esmo.org — Thu, 26 Jun 2025 07:06:00 +00:00

It is intended for the treatment of adult patients with PIK3CA-mutated, ER-positive, HER2- negative locally advanced and metastatic breast cancer

Improved Survival Benefit with Encorafenib plus Cetuximab plus mFOLFOX6 in First-Line Treatment for Patients with BRAF V600E-mutated mCRC

noreply@esmo.org — Wed, 25 Jun 2025 07:06:00 +00:00

Findings from the BREAKWATER study

ESMO Gastrointestinal Cancers Congress 2025, Barcelona, Spain, 2-5 July

noreply@esmo.org — Wed, 25 Jun 2025 06:06:00 +00:00

Neoadjuvant Nivolumab Plus Chemotherapy Improves OS Among Patients with Resectable NSCLC as Compared with Chemotherapy Alone

noreply@esmo.org — Tue, 24 Jun 2025 07:06:00 +00:00

Findings from the CheckMate 816 study

ESMO Advocates for EU Legislation to Prevent Oncologist Burnout and Ensure Sustainable Care for Patients with Cancer

noreply@esmo.org — Mon, 23 Jun 2025 13:06:00 +00:00

Adding Relacorilant To Nab-paclitaxel Prolongs Survival Compared with a Weekly Taxane in Patients with Platinum-Resistant Epithelial Ovarian Cancer

noreply@esmo.org — Mon, 23 Jun 2025 07:06:00 +00:00

Findings from the ROSELLA study

FDA Approves Retifanlimab-dlwr with Carboplatin and Paclitaxel and as a Single Agent for Squamous Cell Carcinoma of the Anal Canal

noreply@esmo.org — Fri, 20 Jun 2025 08:06:00 +00:00

Evidence for efficacy is based on the results from the POD1UM-303/InterAACT 2 and POD1UM-202 studies

EMA Recommends Extension of Therapeutic Indications for Acalabrutinib

noreply@esmo.org — Wed, 18 Jun 2025 08:06:00 +00:00

A new indication concerns the treatment of adult patients with previously untreated CLL in combination with venetoclax

Large DFS Benefit from Adjuvant Cemiplimab Among Patients at High Risk for Recurrence of Cutaneous Squamous Cell Carcinoma

noreply@esmo.org — Wed, 18 Jun 2025 08:06:00 +00:00

Findings from the C-POST study

French Senate Committee Backs ESMO Call to Revise EU Regulation to Support Oncological Research

noreply@esmo.org — Tue, 17 Jun 2025 09:06:00 +00:00

Structured Exercise Programme Initiated Soon After the Completion of Adjuvant Chemotherapy for Colon Cancer Improves DFS

noreply@esmo.org — Tue, 17 Jun 2025 07:06:00 +00:00

Findings from the CO.21 CHALLENGE study

Tarlatamab Prolongs OS Over Chemotherapy Among Patients with SCLC Whose Disease Had Progressed During or After Platinum-Based Chemotherapy

noreply@esmo.org — Mon, 16 Jun 2025 07:06:00 +00:00

Findings from the DeLLphi-304 study

ESMO Announces Results of 2025 Elections

noreply@esmo.org — Sat, 14 Jun 2025 07:06:00 +00:00

ESMO has announced the results of its 2025 elections for key leadership positions, following the closure of the voting system on Tuesday, 10 June 2025.

FDA Grants Accelerated Approval to Telisotuzumab Vedotin-tllv for NSCLC with High c-Met Protein Overexpression

noreply@esmo.org — Fri, 13 Jun 2025 07:06:00 +00:00

Evidence for efficacy is based on the results from the LUMINOSITY study

EMA Recommends Extension of Therapeutic Indications for Brentuximab Vedotin

noreply@esmo.org — Thu, 12 Jun 2025 07:06:00 +00:00

ESMO Calls for Oncology-Specific Safeguards in the EU Critical Medicines Act

noreply@esmo.org — Wed, 11 Jun 2025 09:06:00 +00:00

Ensuring equitable access to cancer treatments remains central to EU health security efforts

Elinzanetant Leads To a Significantly Lower Frequency of Vasomotor Symptoms Associated with Endocrine Therapy for HR-positive Breast Cancer

noreply@esmo.org — Wed, 11 Jun 2025 07:06:00 +00:00

Findings from the OASIS-4 study

ESMO Calls for Cancer to Be at the Core of the European Biotechnology Act, Aiming to Deliver Innovation and Tangible Benefits to Patients with Cancer

noreply@esmo.org — Tue, 10 Jun 2025 22:06:00 +00:00

Vepdegestrant Prolongs PFS in a Subgroup of Patients with ER-positive, HER2-negative Advanced Breast Cancer with ESR1 mutations

noreply@esmo.org — Mon, 30 Jun 2025 07:06:00 +00:00

Findings from the VERITAC-2 study

FDA Approves Darolutamide for Metastatic Castration-Sensitive Prostate Cancer

noreply@esmo.org — Fri, 27 Jun 2025 07:06:00 +00:00

Evidence for efficacy is based on the results from the ARANOTE study

EMA Recommends Granting a Marketing Authorisation for Inavolisib

noreply@esmo.org — Thu, 26 Jun 2025 07:06:00 +00:00

It is intended for the treatment of adult patients with PIK3CA-mutated, ER-positive, HER2- negative locally advanced and metastatic breast cancer

Improved Survival Benefit with Encorafenib plus Cetuximab plus mFOLFOX6 in First-Line Treatment for Patients with BRAF V600E-mutated mCRC

noreply@esmo.org — Wed, 25 Jun 2025 07:06:00 +00:00

Findings from the BREAKWATER study

ESMO Gastrointestinal Cancers Congress 2025, Barcelona, Spain, 2-5 July

noreply@esmo.org — Wed, 25 Jun 2025 06:06:00 +00:00

Neoadjuvant Nivolumab Plus Chemotherapy Improves OS Among Patients with Resectable NSCLC as Compared with Chemotherapy Alone

noreply@esmo.org — Tue, 24 Jun 2025 07:06:00 +00:00

Findings from the CheckMate 816 study

ESMO Advocates for EU Legislation to Prevent Oncologist Burnout and Ensure Sustainable Care for Patients with Cancer

noreply@esmo.org — Mon, 23 Jun 2025 13:06:00 +00:00

Adding Relacorilant To Nab-paclitaxel Prolongs Survival Compared with a Weekly Taxane in Patients with Platinum-Resistant Epithelial Ovarian Cancer

noreply@esmo.org — Mon, 23 Jun 2025 07:06:00 +00:00

Findings from the ROSELLA study

FDA Approves Retifanlimab-dlwr with Carboplatin and Paclitaxel and as a Single Agent for Squamous Cell Carcinoma of the Anal Canal

noreply@esmo.org — Fri, 20 Jun 2025 08:06:00 +00:00

Evidence for efficacy is based on the results from the POD1UM-303/InterAACT 2 and POD1UM-202 studies

EMA Recommends Extension of Therapeutic Indications for Acalabrutinib

noreply@esmo.org — Wed, 18 Jun 2025 08:06:00 +00:00

A new indication concerns the treatment of adult patients with previously untreated CLL in combination with venetoclax

Large DFS Benefit from Adjuvant Cemiplimab Among Patients at High Risk for Recurrence of Cutaneous Squamous Cell Carcinoma

noreply@esmo.org — Wed, 18 Jun 2025 08:06:00 +00:00

Findings from the C-POST study

French Senate Committee Backs ESMO Call to Revise EU Regulation to Support Oncological Research

noreply@esmo.org — Tue, 17 Jun 2025 09:06:00 +00:00

Structured Exercise Programme Initiated Soon After the Completion of Adjuvant Chemotherapy for Colon Cancer Improves DFS

noreply@esmo.org — Tue, 17 Jun 2025 07:06:00 +00:00

Findings from the CO.21 CHALLENGE study

Tarlatamab Prolongs OS Over Chemotherapy Among Patients with SCLC Whose Disease Had Progressed During or After Platinum-Based Chemotherapy

noreply@esmo.org — Mon, 16 Jun 2025 07:06:00 +00:00

Findings from the DeLLphi-304 study

ESMO Announces Results of 2025 Elections

noreply@esmo.org — Sat, 14 Jun 2025 07:06:00 +00:00

ESMO has announced the results of its 2025 elections for key leadership positions, following the closure of the voting system on Tuesday, 10 June 2025.

FDA Grants Accelerated Approval to Telisotuzumab Vedotin-tllv for NSCLC with High c-Met Protein Overexpression

noreply@esmo.org — Fri, 13 Jun 2025 07:06:00 +00:00

Evidence for efficacy is based on the results from the LUMINOSITY study

EMA Recommends Extension of Therapeutic Indications for Brentuximab Vedotin

noreply@esmo.org — Thu, 12 Jun 2025 07:06:00 +00:00

ESMO Calls for Oncology-Specific Safeguards in the EU Critical Medicines Act

noreply@esmo.org — Wed, 11 Jun 2025 09:06:00 +00:00

Ensuring equitable access to cancer treatments remains central to EU health security efforts

Elinzanetant Leads To a Significantly Lower Frequency of Vasomotor Symptoms Associated with Endocrine Therapy for HR-positive Breast Cancer

noreply@esmo.org — Wed, 11 Jun 2025 07:06:00 +00:00

Findings from the OASIS-4 study

ESMO Calls for Cancer to Be at the Core of the European Biotechnology Act, Aiming to Deliver Innovation and Tangible Benefits to Patients with Cancer

noreply@esmo.org — Tue, 10 Jun 2025 22:06:00 +00:00

Vepdegestrant Prolongs PFS in a Subgroup of Patients with ER-positive, HER2-negative Advanced Breast Cancer with ESR1 mutations

noreply@esmo.org — Mon, 30 Jun 2025 07:06:00 +00:00

Findings from the VERITAC-2 study

FDA Approves Darolutamide for Metastatic Castration-Sensitive Prostate Cancer

noreply@esmo.org — Fri, 27 Jun 2025 07:06:00 +00:00

Evidence for efficacy is based on the results from the ARANOTE study

EMA Recommends Granting a Marketing Authorisation for Inavolisib

noreply@esmo.org — Thu, 26 Jun 2025 07:06:00 +00:00

It is intended for the treatment of adult patients with PIK3CA-mutated, ER-positive, HER2- negative locally advanced and metastatic breast cancer

Improved Survival Benefit with Encorafenib plus Cetuximab plus mFOLFOX6 in First-Line Treatment for Patients with BRAF V600E-mutated mCRC

noreply@esmo.org — Wed, 25 Jun 2025 07:06:00 +00:00

Findings from the BREAKWATER study

ESMO Gastrointestinal Cancers Congress 2025, Barcelona, Spain, 2-5 July

noreply@esmo.org — Wed, 25 Jun 2025 06:06:00 +00:00

Neoadjuvant Nivolumab Plus Chemotherapy Improves OS Among Patients with Resectable NSCLC as Compared with Chemotherapy Alone

noreply@esmo.org — Tue, 24 Jun 2025 07:06:00 +00:00

Findings from the CheckMate 816 study

ESMO Advocates for EU Legislation to Prevent Oncologist Burnout and Ensure Sustainable Care for Patients with Cancer

noreply@esmo.org — Mon, 23 Jun 2025 13:06:00 +00:00

Adding Relacorilant To Nab-paclitaxel Prolongs Survival Compared with a Weekly Taxane in Patients with Platinum-Resistant Epithelial Ovarian Cancer

noreply@esmo.org — Mon, 23 Jun 2025 07:06:00 +00:00

Findings from the ROSELLA study

FDA Approves Retifanlimab-dlwr with Carboplatin and Paclitaxel and as a Single Agent for Squamous Cell Carcinoma of the Anal Canal

noreply@esmo.org — Fri, 20 Jun 2025 08:06:00 +00:00

Evidence for efficacy is based on the results from the POD1UM-303/InterAACT 2 and POD1UM-202 studies

EMA Recommends Extension of Therapeutic Indications for Acalabrutinib

noreply@esmo.org — Wed, 18 Jun 2025 08:06:00 +00:00

A new indication concerns the treatment of adult patients with previously untreated CLL in combination with venetoclax

Large DFS Benefit from Adjuvant Cemiplimab Among Patients at High Risk for Recurrence of Cutaneous Squamous Cell Carcinoma

noreply@esmo.org — Wed, 18 Jun 2025 08:06:00 +00:00

Findings from the C-POST study

French Senate Committee Backs ESMO Call to Revise EU Regulation to Support Oncological Research

noreply@esmo.org — Tue, 17 Jun 2025 09:06:00 +00:00

Structured Exercise Programme Initiated Soon After the Completion of Adjuvant Chemotherapy for Colon Cancer Improves DFS

noreply@esmo.org — Tue, 17 Jun 2025 07:06:00 +00:00

Findings from the CO.21 CHALLENGE study

Tarlatamab Prolongs OS Over Chemotherapy Among Patients with SCLC Whose Disease Had Progressed During or After Platinum-Based Chemotherapy

noreply@esmo.org — Mon, 16 Jun 2025 07:06:00 +00:00

Findings from the DeLLphi-304 study

ESMO Announces Results of 2025 Elections

noreply@esmo.org — Sat, 14 Jun 2025 07:06:00 +00:00

ESMO has announced the results of its 2025 elections for key leadership positions, following the closure of the voting system on Tuesday, 10 June 2025.

FDA Grants Accelerated Approval to Telisotuzumab Vedotin-tllv for NSCLC with High c-Met Protein Overexpression

noreply@esmo.org — Fri, 13 Jun 2025 07:06:00 +00:00

Evidence for efficacy is based on the results from the LUMINOSITY study

EMA Recommends Extension of Therapeutic Indications for Brentuximab Vedotin

noreply@esmo.org — Thu, 12 Jun 2025 07:06:00 +00:00

ESMO Calls for Oncology-Specific Safeguards in the EU Critical Medicines Act

noreply@esmo.org — Wed, 11 Jun 2025 09:06:00 +00:00

Ensuring equitable access to cancer treatments remains central to EU health security efforts

Elinzanetant Leads To a Significantly Lower Frequency of Vasomotor Symptoms Associated with Endocrine Therapy for HR-positive Breast Cancer

noreply@esmo.org — Wed, 11 Jun 2025 07:06:00 +00:00

Findings from the OASIS-4 study

ESMO Calls for Cancer to Be at the Core of the European Biotechnology Act, Aiming to Deliver Innovation and Tangible Benefits to Patients with Cancer

noreply@esmo.org — Tue, 10 Jun 2025 22:06:00 +00:00